IL1B and type 2 diabetes mellitus: Once released, IL-1b can amplify its signals by self-activation via engagement of the IL-1 receptor I leading to a vicious cycle of inflammation.[4] Therefore, we hypothesize that regulating caspase-3 activity may protect beta cells, thereby serving as a therapeutic approach for T2DM.